What is the 13F Pro Quality Score for BVS?

13F Pro ranks Bioventus Inc. (BVS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BVS's current score at https://13fpro.ai/company/BVS (free sign-up required for the full ranking).

Where does 13F Pro source BVS data?

All Bioventus Inc. fundamentals and ownership data come directly from SEC EDGAR. Bioventus Inc. files with the SEC under CIK 1665988. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BVS in?

Bioventus Inc. (BVS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BVS's revenue?

Per Bioventus Inc.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: U.S. Pain Treatments ($72.7M, +12.8% YoY); U.S. Surgical Solutions ($43.6M, -4.7% YoY); U.S. Restorative Therapies ($18.2M, -2.2% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BVS.

How often is BVS research updated on 13F Pro?

BVS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Bioventus Inc.(BVS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1665988 BVS stock profile & AI dashboard →

13F Pro Quality Score

59.9/100

Rank #903 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

39.1/100

Profitability

72.0/100

Balance Sheet

80.4/100

Earnings Quality

80.5/100

Free Cash Flow

67.0/100

Institutional Flow

78.3/100

Revenue Scale

39.4/100

Dilution Risk

38.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BVS Scores 60/100

exact factor attribution · 2026-09-11

BVS's composite is driven by profitability and earnings quality, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+3.3 pts

72th pct

Earnings quality

+3.0 pts

81th pct

Capital efficiency

+3.0 pts

80th pct

Free cash flow

+2.5 pts

67th pct

Institutional flow

+1.4 pts

78th pct

Earnings growth

+0.9 pts

68th pct

Shareholder dilution

-0.6 pts

38th pct

Scale

-1.6 pts

39th pct

Revenue growth

-2.2 pts

39th pct

Latest change (2026-08-05): 50 → 52 · ↑ Free cash flow 59→75

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BVS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Bioventus Inc. (BVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BVS at 59.9/100 on a 32-signal composite quality model, placing it at rank #903 of 2,962 stocks — the top half of the AI-ranked universe. BVS scores in the top quartile across earnings quality (80.5), balance sheet strength (80.4), institutional flow (78.3). Areas of concern include revenue growth (39.1) and revenue scale (39.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bioventus Inc. reports quarterly revenue of $153.2M, net income of $33.4M, an operating margin of 12.5%. Top institutional holders of BVS by reported 13-F value include Essex Woodlands Management, Juniper Investment Company, Nantahala Capital Management, based on the most recent SEC filings. BVS trades on the Nasdaq exchange and files with the SEC under CIK 1665988. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bioventus Inc. directly from SEC EDGAR. Bioventus Inc.'s 13F Pro composite quality score has ranged between 32 and 60 since 2022, currently 59.9 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about Bioventus Inc.

Quirks, history, and lore behind BVS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Annual revenue in the range of $500 million, with a product portfolio spanning dozens of SKUs sold largely through physicians, orthopedic surgeons, and outpatient clinics.
3
The History
The company went public in 2021, carving itself out of a larger medical-device parent to stand alone as a specialist in non-surgical, biological treatments for musculoskeletal conditions.
4
The Secret
Its core belief: skip the operating room. It sells products designed to help the body heal bone, joint, and soft tissue without a surgeon's scalpel — think bone grafts, hyaluronic acid injections, and platelet-rich plasma.
5
The Lore
The name itself is a mashup of biology and venture — fitting for a company that bets on the body's own healing pathways rather than implants or drugs.
6
The Giveaway
Ticker BVS, Durham-based, laser-focused on musculoskeletal healing without surgery — this is the company that wants your creaky knee fixed with biology, not a blade.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BVS's Business? Latest 10-Q Breakdown

✓ 25/25 datapoints verified

AI-extracted from Bioventus Inc.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue $153.2M (+3.8% YoY) driven by Pain Treatments growth; $24.6M tax benefit from valuation allowance release more than doubled net income to $36.2M.

Biggest Revenue Drivers

U.S. Pain Treatments$72.7M+12.8% YoY

9.3% volume growth led by Durolane plus 3.6% price growth from favorable rebates and customer mix.

U.S. Surgical Solutions$43.6M-4.7% YoY

Lower Ultrasonics volumes offset growth in other categories.

Biggest Revenue Drivers

Total revenue: $153.2M+3.8% YoY

U.S. Pain Treatments$72.7M+12.8% YoY

9.3% volume growth led by Durolane plus 3.6% price growth from favorable rebates and customer mix.

U.S. Surgical Solutions$43.6M-4.7% YoY

Lower Ultrasonics volumes offset growth in other categories.

U.S. Restorative Therapies$18.2M-2.2% YoY

Unfavorable customer mix for EXOGEN Bone Stimulation System.

International$18.7M-0.8% YoY

Essentially flat; Pain Treatments growth offset by declines in Surgical Solutions and Restorative Therapies.

Largest Expense Items

Selling, general and administrative$82.7M+4.6% YoY

Higher professional service costs including legal-related expenses, increased stock-based compensation, and higher sales commissions.

Cost of sales (including depreciation and amortization)$47.5M+4.3% YoY

Higher freight, manufacturing variances, and unfavorable EXOGEN ASP, partially offset by lower depreciation.

Research and development$3.2MFlat YoY

Consulting expenses offset by compensation-related cost increases.

Margins: Gross margin declined 10 basis points to 69.0% due to freight headwinds (40bps), lower EXOGEN ASP (30bps), and scrap/manufacturing charges (20bps), partially offset by 70bps benefit from lower depreciation. Operating margin improved to 12.5% from 12.4% YoY despite SG&A deleveraging.

Watch Items from the Filing

One customer represents 13.3% of Q2 revenue ($20.4M) and 27.7% of accounts receivable; customer concentration risk on rebate volatility and payment timing.
Rebate estimate changes on U.S. HA products represented 2.8% of U.S. segment revenue in Q2 2026 vs. 2.1% in Q2 2025; increased volatility from third-party billing process changes.
Board conducting strategic alternatives review following unsolicited acquisition proposal; process could distract management, result in litigation costs, and adversely affect employee retention and business operations.
Multiple shareholder derivative lawsuits consolidated; two settlement-in-principle reached July 17, 2026 limited to corporate governance reforms with no material attorney fee awards expected.
Discretionary debt prepayments of $42M in first half 2026 reduce interest burden; outstanding term loan $248.5M vs. $296.3M at year-end 2025; leverage ratio improving.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$153.2M

Net Income

Q2 2026

$33.4M

Free Cash Flow

Q2 2026

$18.9M

Operating Margin

Q2 2026

12.5%

ROIC

Q2 2026

16.1%

D/E Ratio

Q2 2026

1.09

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-0.9% YoY

$568.1MFY 2025

FY22 $512.1MFY23 $512.3MFY24 $573.3MFY25 $568.1M

Net Income

+162.9% YoY

$22.7MFY 2025

FY22 $-158.7MFY23 $-156.2MFY24 $-36.1MFY25 $22.7M

Operating Income

+455.2% YoY

$54.0MFY 2025

FY22 $-167.2MFY23 $-81.7MFY24 $-15.2MFY25 $54.0M

EPS (Diluted)

+158.9% YoY

$0.33FY 2025

FY22 $-2.59FY23 $-2.49FY24 $-0.56FY25 $0.33

Total Assets

-6.1% YoY

$683.6MFY 2025

FY22 $1.37BFY23 $810.9MFY24 $728.0MFY25 $683.6M

Total Debt

-12.4% YoY

$294.0MFY 2025

FY22 $418.1MFY23 $394.8MFY24 $335.6MFY25 $294.0M

Op. Cash Flow

+92.5% YoY

$74.7MFY 2025

FY22 $-13.5MFY23 $15.3MFY24 $38.8MFY25 $74.7M

Free Cash Flow

+90.8% YoY

$72.1MFY 2025

FY22 $-15.0MFY23 $8.0MFY24 $37.8MFY25 $72.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$568.1M -0.9%	$573.3M +11.9%	$512.3M +0.0%	$512.1M +18.8%	$430.9M +34.2%	$321.2M
Net Income	$22.7M +162.9%	$-36.1M +76.9%	$-156.2M +1.6%	$-158.7M -919.1%	$19.4M +18.1%	$16.4M
Operating Income	$54.0M +455.2%	$-15.2M +81.4%	$-81.7M +51.1%	$-167.2M -1486.6%	$12.1M -43.2%	$21.2M
EPS (Diluted)	$0.33 +158.9%	$-0.56 +77.5%	$-2.49 +3.9%	$-2.59 -1626.7%	$-0.15	—
Total Assets	$683.6M -6.1%	$728.0M -10.2%	$810.9M -40.9%	$1.37B +12.0%	$1.23B +147.9%	$494.5M
Total Debt	$294.0M -12.4%	$335.6M -15.0%	$394.8M -5.6%	$418.1M +11.3%	$375.7M +99.5%	$188.4M
Operating Cash Flow	$74.7M +92.5%	$38.8M +152.8%	$15.3M +213.3%	$-13.5M -158.9%	$23.0M -68.0%	$71.8M
Free Cash Flow	$72.1M +90.8%	$37.8M +373.4%	$8.0M +153.2%	$-15.0M -258.5%	$9.5M -82.8%	$55.2M

Get alerted when BVS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bioventus Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BVS

Essex Woodlands Management, Inc.
$122.9M13,021,324 sh
Juniper Investment Company, LLC
$65.5M6,939,357 sh
Nantahala Capital Management, LLC
$56.6M6,000,279 sh
BlackRock, Inc.
$32.4M3,435,914 sh
ROYCE & ASSOCIATES LP
$17.3M1,833,212 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.5M1,751,678 sh
GEODE CAPITAL MANAGEMENT, LLC
$12.9M1,365,716 sh
AMERICAN CENTURY COMPANIES INC
$12.8M1,353,415 sh
DIMENSIONAL FUND ADVISORS LP
$10.7M1,128,465 sh
STATE STREET CORP
$10.4M1,104,878 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$122.9M	13,021,324
Juniper Investment Company, LLC	$65.5M	6,939,357
Nantahala Capital Management, LLC	$56.6M	6,000,279
BlackRock, Inc.	$32.4M	3,435,914
ROYCE & ASSOCIATES LP	$17.3M	1,833,212
VANGUARD CAPITAL MANAGEMENT LLC	$16.5M	1,751,678
GEODE CAPITAL MANAGEMENT, LLC	$12.9M	1,365,716
AMERICAN CENTURY COMPANIES INC	$12.8M	1,353,415
DIMENSIONAL FUND ADVISORS LP	$10.7M	1,128,465
STATE STREET CORP	$10.4M	1,104,878

Companies Similar to BVS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VMD

VIEMED HEALTHCARE, INC.

AI score

Similar quality profile · 11 shared holders

Nantahala Capital Management, LLC Kent Lake PR LLC TOCQUEVILLE ASSET MANAGEMENT L.P.

Pediatrix Medical Group, Inc.

AI score

Similar quality profile · 10 shared holders

ROYCE & ASSOCIATES LP Hillsdale Investment Management Inc.OBERWEIS ASSET MANAGEMENT INC/

MDXG

MIMEDX GROUP, INC.

AI score

Similar quality profile · 5 shared holders

Essex Woodlands Management, Inc.Nantahala Capital Management, LLC KENNEDY CAPITAL MANAGEMENT LLC

PBYI

PUMA BIOTECHNOLOGY, INC.

AI score

Similar quality profile · 6 shared holders

KENNEDY CAPITAL MANAGEMENT LLC GLOBEFLEX CAPITAL L P LSV ASSET MANAGEMENT

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 9 shared holders

OBERWEIS ASSET MANAGEMENT INC/KENNEDY CAPITAL MANAGEMENT LLC WEDGE CAPITAL MANAGEMENT L L P/NC

AMRX

Amneal Pharmaceuticals, Inc.

AI score

Similar quality profile · 7 shared holders

Nantahala Capital Management, LLC Hillsdale Investment Management Inc.GLOBEFLEX CAPITAL L P

AORT

ARTIVION, INC.

AI score

Similar quality profile · 5 shared holders

Juniper Investment Company, LLC ROYCE & ASSOCIATES LP KENNEDY CAPITAL MANAGEMENT LLC

GRDN

Guardian Pharmacy Services, Inc.

AI score

Similar quality profile · 4 shared holders

ROYCE & ASSOCIATES LP GLOBEFLEX CAPITAL L P VARCOV Co.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BVS on your watchlist

Track score changes the day Bioventus Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BVS a good stock to buy?

13F Pro's AI-powered analysis of Bioventus Inc. (BVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BVS are available on the BVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BVS is classified as a small company.

Which hedge funds own BVS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bioventus Inc.'s investment landscape.